PPARγ Pro12Ala polymorphism and risk of acute coronary syndrome in a prospective study of Danes

[1]  E. Rimm,et al.  S447X variant of the lipoprotein lipase gene, lipids, and risk of coronary heart disease in 3 prospective cohort studies. , 2009, American heart journal.

[2]  C. Dethlefsen,et al.  Predictive values of acute coronary syndrome discharge diagnoses differed in the Danish National Patient Registry. , 2009, Journal of clinical epidemiology.

[3]  D. Grobbee,et al.  Peroxisome proliferator-activated receptor gamma-2 P12A polymorphism and risk of acute myocardial infarction, coronary heart disease and ischemic stroke: A case-cohort study and meta-analyses , 2008, Vascular health and risk management.

[4]  U. Vogel,et al.  Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. , 2008, Mutation research.

[5]  U. Vogel,et al.  Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. , 2007, Mutation research.

[6]  J. Auwerx,et al.  PPARγ in human and mouse physiology , 2007 .

[7]  A. Tjønneland,et al.  Study design, exposure variables, and socioeconomic determinants of participation in Diet, Cancer and Health: A population-based prospective cohort study of 57,053 men and women in Denmark , 2007, Scandinavian journal of public health.

[8]  M. Stumvoll,et al.  The role of the Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ in diabetes risk , 2007, Current opinion in clinical nutrition and metabolic care.

[9]  U. Vogel,et al.  Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. , 2007, Mutation research.

[10]  U. Vogel,et al.  Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. , 2006, Carcinogenesis.

[11]  J. Auwerx,et al.  PPARgamma in human and mouse physiology. , 2007, Biochimica et biophysica acta.

[12]  Tang-chun Wu,et al.  Association between Pro12Ala polymorphism of peroxisome proliferator‐activated receptor‐gamma 2 and myocardial infarction in the Chinese Han population , 2006, Clinical cardiology.

[13]  J. Manson,et al.  Peroxisome Proliferator-Activated Receptor-γ2 P12A Polymorphism and Risk of Coronary Heart Disease in US Men and Women , 2005 .

[14]  J. Staessen,et al.  Alcohol intake modulates the genetic association between HDL cholesterol and the PPARgamma2 Pro12Ala polymorphism. , 2005, Journal of lipid research.

[15]  J. Manson,et al.  Peroxisome proliferator-activated receptor-gamma2 P12A polymorphism and risk of coronary heart disease in US men and women. , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[16]  A. Morris,et al.  Cardiovascular Risk in Type 2 Diabetes Is Associated With Variation at the PPARG Locus: A Go-DARTS Study , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[17]  P. Amouyel,et al.  Impact of genetic variation of PPARγ in humans , 2004 .

[18]  M. Fu,et al.  Selective disruption of PPARγ2 impairs the development of adipose tissue and insulin sensitivity , 2004 .

[19]  P. Amouyel,et al.  Impact of genetic variation of PPARgamma in humans. , 2004, Molecular genetics and metabolism.

[20]  M. Fu,et al.  Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Doney,et al.  Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes , 2004, Diabetologia.

[22]  N. Cook,et al.  Alanine for Proline Substitution in the Peroxisome Proliferator–Activated Receptor Gamma-2 (PPARG2) Gene and the Risk of Incident Myocardial Infarction , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[23]  A. Morris,et al.  Haplotype analysis of the PPARγ Pro12Ala and C1431T variants reveals opposing associations with body weight , 2002, BMC Genetics.

[24]  M. Stumvoll,et al.  The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism , 2002 .

[25]  M. Stumvoll,et al.  The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. , 2002, Diabetes.

[26]  Gerd Geisslinger,et al.  Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  J. Beilby,et al.  A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. , 2001, European journal of endocrinology.

[28]  M. Daly,et al.  Guilt by association , 2000, Nature Genetics.

[29]  M. Kasuga,et al.  Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. , 2000, Biochemical and biophysical research communications.

[30]  E S Lander,et al.  The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. , 2000, Nature genetics.

[31]  Johan Auwerx,et al.  A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity , 1998, Nature Genetics.

[32]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[33]  J F Lawless,et al.  Likelihood analysis of multi-state models for disease incidence and mortality. , 1988, Statistics in medicine.